rivastigmine + memantine

Rivastigmine + memantine is a combination therapy used in the management of mild to moderate dementia, particularly in Alzheimer's disease. Rivastigmine is a reversible cholinesterase inhibitor that increases acetylcholine levels by inhibiting its breakdown, thereby enhancing cholinergic neurotransmission in the brain[7][2]. Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, which blocks excessive glutamatergic activity and prevents excitotoxicity associated with neurodegeneration[6][8]. The combination aims to address multiple pathological mechanisms underlying cognitive decline in Alzheimer's disease. Clinical studies suggest that this combination can improve cognitive function and is generally well tolerated[5].